Nuvalent (NUVL) Competitors $91.17 +0.11 (+0.12%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NUVL vs. KDNY, PRAX, IGMS, OCGN, GOSS, TEVA, BGNE, VTRS, SMMT, and MRNAShould you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Chinook Therapeutics (KDNY), Praxis Precision Medicines (PRAX), IGM Biosciences (IGMS), Ocugen (OCGN), Gossamer Bio (GOSS), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Summit Therapeutics (SMMT), and Moderna (MRNA). These companies are all part of the "medical" sector. Nuvalent vs. Chinook Therapeutics Praxis Precision Medicines IGM Biosciences Ocugen Gossamer Bio Teva Pharmaceutical Industries BeiGene Viatris Summit Therapeutics Moderna Nuvalent (NASDAQ:NUVL) and Chinook Therapeutics (NASDAQ:KDNY) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, community ranking, risk and profitability. Do analysts recommend NUVL or KDNY? Nuvalent presently has a consensus target price of $112.60, indicating a potential upside of 23.51%. Given Nuvalent's stronger consensus rating and higher probable upside, equities analysts plainly believe Nuvalent is more favorable than Chinook Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvalent 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.85Chinook Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher valuation & earnings, NUVL or KDNY? Nuvalent has higher earnings, but lower revenue than Chinook Therapeutics. Nuvalent is trading at a lower price-to-earnings ratio than Chinook Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvalentN/AN/A-$126.22M-$3.47-26.27Chinook Therapeutics$6.13M473.15-$187.87M-$3.52-11.47 Does the MarketBeat Community favor NUVL or KDNY? Nuvalent received 13 more outperform votes than Chinook Therapeutics when rated by MarketBeat users. Likewise, 76.92% of users gave Nuvalent an outperform vote while only 50.00% of users gave Chinook Therapeutics an outperform vote. CompanyUnderperformOutperformNuvalentOutperform Votes4076.92% Underperform Votes1223.08% Chinook TherapeuticsOutperform Votes2750.00% Underperform Votes2750.00% Do institutionals and insiders believe in NUVL or KDNY? 97.3% of Nuvalent shares are owned by institutional investors. Comparatively, 95.2% of Chinook Therapeutics shares are owned by institutional investors. 12.5% of Nuvalent shares are owned by insiders. Comparatively, 16.8% of Chinook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is NUVL or KDNY more profitable? Nuvalent has a net margin of 0.00% compared to Chinook Therapeutics' net margin of -4,199.93%. Nuvalent's return on equity of -28.63% beat Chinook Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets NuvalentN/A -28.63% -27.15% Chinook Therapeutics -4,199.93%-58.28%-44.72% Which has more risk & volatility, NUVL or KDNY? Nuvalent has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Chinook Therapeutics has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Does the media favor NUVL or KDNY? In the previous week, Nuvalent had 14 more articles in the media than Chinook Therapeutics. MarketBeat recorded 14 mentions for Nuvalent and 0 mentions for Chinook Therapeutics. Chinook Therapeutics' average media sentiment score of 0.67 beat Nuvalent's score of 0.40 indicating that Chinook Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Nuvalent Neutral Chinook Therapeutics Positive SummaryNuvalent beats Chinook Therapeutics on 14 of the 18 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Nuvalent News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVL vs. The Competition Export to ExcelMetricNuvalentPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.91B$6.41B$5.01B$8.81BDividend YieldN/A8.11%5.21%4.07%P/E Ratio-26.2710.02126.5217.52Price / SalesN/A318.981,203.9085.12Price / CashN/A22.1633.3732.51Price / Book8.335.464.684.68Net Income-$126.22M$152.97M$118.36M$225.62M7 Day Performance0.92%-4.33%-2.46%-2.04%1 Month Performance-12.07%-8.65%-4.06%0.03%1 Year Performance51.09%28.53%29.55%24.47% Nuvalent Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVLNuvalent2.1677 of 5 stars$91.17+0.1%$112.60+23.5%+51.1%$5.90BN/A-26.2740KDNYChinook TherapeuticsN/A$40.39flatN/AN/A$2.90B$6.13M-11.47214PRAXPraxis Precision Medicines1.754 of 5 stars$73.68+1.3%$146.33+98.6%+299.3%$1.36B$2.45M0.00110IGMSIGM Biosciences4.693 of 5 stars$9.77+2.4%$16.13+65.1%+63.3%$580.63M$2.13M-2.68190OCGNOcugen1.3147 of 5 stars$0.92+4.6%$5.67+516.9%+124.1%$267.58M$6.04M-5.1065Analyst ForecastGOSSGossamer Bio4.4287 of 5 stars$0.70-2.8%$9.20+1,220.9%-16.9%$157.83M$105.32M-2.19180TEVATeva Pharmaceutical Industries2.6924 of 5 stars$17.03+1.2%$19.67+15.5%+80.0%$19.04B$15.85B0.0037,851BGNEBeiGene3.174 of 5 stars$194.26+3.5%$247.07+27.2%+3.4%$18.92B$2.46B-23.5810,600Analyst DowngradeGap UpVTRSViatris1.3448 of 5 stars$13.13+0.6%$13.33+1.5%+38.6%$15.58B$15.43B0.0038,000SMMTSummit Therapeutics1.863 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.000.00105Analyst ForecastMRNAModerna4.6267 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.35B$6.85B0.005,600Analyst UpgradeAnalyst Revision Related Companies and Tools Related Companies KDNY Competitors PRAX Competitors IGMS Competitors OCGN Competitors GOSS Competitors TEVA Competitors BGNE Competitors VTRS Competitors SMMT Competitors MRNA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NUVL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
